Home / Market News / $VRTX

$VRTX news and market catalysts

The 35 most recent market catalysts affecting $VRTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

35 catalysts 2 high impact 25 bullish 3 bearish Technology
Nov 16, 2026 Corporate Catalyst Bullish Impact 75
Virtuix Reports Second Quarter Fiscal 2027 Financial Results
Virtuix Holdings Inc. reported its Q2 FY27 financial results, showcasing significant growth with Omni One revenue up 105% to $1.1 million and total company revenue increasing by 21…
Nov 11, 2026 Energy/Commodity Neutral Impact 55
Vortex Energy Corp. Commences Ground Gravity Survey at Robinsons River Salt Project
Vortex Energy Corp. announced the commencement of a ground gravity data acquisition program at its Robinsons River Salt Project. This survey is a standard procedure in mineral expl…
Nov 10, 2026 Corporate Catalyst Bullish Impact 55
Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals
Daiwa Securities, a prominent financial firm, has raised its price target for Vertex Pharmaceuticals (VRTX) from $556 to $640. This adjustment indicates a more optimistic assessmen…
Nov 9, 2026 Corporate Catalyst Bearish Impact 65
Evotec Announces Manufacturing Pause for Vertex's Povetacicept
Evotec, a manufacturing partner for Vertex Pharmaceuticals, is temporarily pausing the commercial manufacturing of Vertex's investigational drug povetacicept. This pause is necessa…
Nov 6, 2026 Corporate Catalyst Bullish Impact 55
Needham Maintains Buy Rating and Raises Price Target for Vertex Pharmaceuticals
Needham, a financial firm, maintained its 'Buy' rating on Vertex Pharmaceuticals and raised its price target from $20 to $30. This action reflects an updated positive outlook on th…
Nov 4, 2026 Corporate Catalyst Bullish Impact 55
Bernstein Increases Price Target on Vertex Pharmaceuticals
Bernstein has raised its price target for Vertex Pharmaceuticals (VRTX) to $620 from $608. This revision indicates a more optimistic outlook from the analyst firm, likely driven by…
Nov 4, 2026 Corporate Catalyst Bullish Impact 55
Barclays Raises Vertex Pharmaceuticals Price Target to $626
Barclays, a prominent financial institution, adjusted its price target for Vertex Pharmaceuticals (VRTX) from $617 to $626 on November 4, 2026. This action reflects a revised valua…
Nov 3, 2026 Corporate Catalyst Neutral Impact 65
Multiple Analysts Adjust Price Targets for Vertex Pharmaceuticals
This 8-K filing discloses that several prominent investment firms, including Goldman Sachs and Morgan Stanley, updated their price targets for Vertex Pharmaceuticals (VRTX) on Nove…
Nov 3, 2026 Corporate Catalyst Bullish Impact 55
Scotiabank Adjusts Price Target on Vertex Pharmaceuticals
Scotiabank has raised its price target for Vertex Pharmaceuticals (VRTX) from $558 to $660. This upward revision indicates that Scotiabank's analysts have a more optimistic view of…
Nov 3, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Markets Raises Price Target on Vertex Pharmaceuticals to $600
RBC Capital Markets updated its outlook on Vertex Pharmaceuticals, raising its price target from $576 to $600 and reiterating an 'Outperform' rating. This positive adjustment is pr…
Nov 3, 2026 Corporate Catalyst Bullish Impact 55
Scotiabank Adjusts Price Target on Vertex Pharmaceuticals to $660
Scotiabank revised its price target for Vertex Pharmaceuticals (VRTX) upwards to $660 from $558. This analyst upgrade reflects a more optimistic view on the company's valuation and…
Nov 3, 2026 Corporate Catalyst Bullish Impact 55
UBS Adjusts Price Target on Vertex Pharmaceuticals to $640 From $615
UBS, a prominent financial institution, has adjusted its price target for Vertex Pharmaceuticals (VRTX) upwards, from $615 to $640, while maintaining a 'Buy' rating. This action si…
Nov 2, 2026 Corporate Catalyst Bullish Impact 85
Vertex Pharmaceuticals Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
Vertex Pharmaceuticals announced impressive third-quarter 2026 financial results, with total revenue reaching $3.44 billion, a 12% increase year-over-year. This strong performance,…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
Virtuix Secures 27th U.S. Patent for Proprietary Footwear Technology
Virtuix Holdings Inc. has secured its 27th U.S. patent, specifically for footwear technology designed to improve user experience on its omni-directional treadmills. This developmen…
Oct 30, 2026 Corporate Catalyst Bullish Impact 65
UK Healthcare Regulator Approves Vertex Pharmaceuticals' Casgevy for Children Aged Five and Older
The UK's MHRA has approved Vertex Pharmaceuticals' Casgevy for children aged five and older, expanding its previous authorization for those 12 and older. This is a significant posi…
Oct 28, 2026 Corporate Catalyst Bullish Impact 75
Virtuix Announces Preliminary Q2 FY2027 Revenue Growth and Schedules Earnings Call
Virtuix Holdings Inc. has pre-announced strong revenue growth for Q2 FY2027, a significant positive indicator for the company. This growth is primarily driven by the successful lau…
Oct 24, 2026 Corporate Catalyst Neutral Impact 75
Vertex Pharmaceuticals Announces Publication of Phase 3 RAINIER Results for Povetacicept
Vertex Pharmaceuticals announced the publication of Phase 3 RAINIER study results for povetacicept in the New England Journal of Medicine and presented them at ASN Kidney Week 2026…
Oct 22, 2026 Corporate Catalyst Bullish Impact 55
Vortex Energy Corp. Receives Government Approval for Ground Gravity Survey
Vortex Energy Corp. announced government approval for a ground gravity survey at its Robinsons River Salt Project. This is a necessary step for the company to advance its technical…
Oct 9, 2026 Corporate Catalyst Neutral Impact 75
Vertex Presents Study Reporting ALYFTREK Data Shows Pancreatic Function Recovery In Some Children Ages 2–5 With Cystic Fibrosis
Vertex Pharmaceuticals announced positive interim data for its drug ALYFTREK, showing recovery of pancreatic function in some young cystic fibrosis patients. This is significant be…
Oct 8, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $576
RBC Capital's analyst Brian Abrahams maintained an 'Outperform' rating on Vertex Pharmaceuticals and slightly raised the price target from $570 to $576. This action signals continu…
Sep 28, 2026 Corporate Catalyst Bullish Impact 55
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $615
UBS analyst Michael Yee maintained a 'Buy' rating on Vertex Pharmaceuticals (VRTX) and raised the price target from $585 to $615. This action signals continued bullish sentiment fr…
Sep 22, 2026 Corporate Catalyst Bullish Impact 75
Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug
Vertex Pharmaceuticals announced encouraging Phase 2b results for inaxaplin, a drug targeting APOL1-mediated kidney disease (AMKD). The data showed significant reductions in protei…
Sep 22, 2026 Corporate Catalyst Bullish Impact 85
Vertex Pharmaceuticals shares are trading higher after the company announced results from a study of its inaxaplin candidate that showed a reduction in urine albumin to creatinine ratio at week 13 and was generally safe and well tolerated.
The positive clinical trial results for Vertex Pharmaceuticals' inaxaplin candidate are a significant corporate catalyst. The reduction in urine albumin to creatinine ratio, couple…
Sep 15, 2026 Corporate Catalyst Neutral Impact 55
Virtuix Announces Sale Of Omni One Systems To The U.S. Department Of Veterans Affairs; Terms Not Disclosed
Virtuix has secured its first sale of Omni One virtual reality systems to the U.S. Department of Veterans Affairs, specifically for deployment at the Valor Center in Detroit. This …
Sep 2, 2026 Corporate Catalyst Neutral Impact 65
Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target
Morgan Stanley analyst Terence Flynn has reinstated an 'Overweight' rating on Vertex Pharmaceuticals (VRTX) and announced a $665 price target. This action signals a strong belief i…
Aug 25, 2026 Corporate Catalyst Neutral Impact 65
Live On CNBC, Karen Firestone Announces Bought Vertex Pharmaceuticals
This announcement serves as a positive catalyst for Vertex Pharmaceuticals (VRTX) due to the 'smart money' endorsement from Karen Firestone, a respected figure in finance. While no…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565
Truist Securities analyst Danielle Brill has maintained a 'Buy' rating on Vertex Pharmaceuticals (VRTX) and raised the price target from $560 to $565. This action signals continued…
Aug 4, 2026 Corporate Catalyst Bullish Impact 55
TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550
TD Cowen analyst Phil Nadeau has maintained a 'Buy' rating on Vertex Pharmaceuticals (VRTX) and raised the price target from $525 to $550. This action signals continued bullish sen…
Aug 4, 2026 Corporate Catalyst Bearish Impact 75
Vertex shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.
This headline signals a negative sentiment shift for Vertex Pharmaceuticals, driven by professional analysts re-evaluating the stock's potential. Lowered price targets often preced…
Aug 4, 2026 Corporate Catalyst Bullish Impact 55
Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $595
This filing discloses that Cantor Fitzgerald analyst Carter Gould has maintained an 'Overweight' rating on Vertex Pharmaceuticals (VRTX) and raised the price target from $590 to $5…
Aug 3, 2026 Corporate Catalyst Bullish Impact 75
Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est
Vertex Pharmaceuticals announced an upward revision to its FY2026 sales guidance, moving from $12.950B-$13.100B to $13.100B-$13.200B. This is significant as the new lower bound ($1…
Aug 3, 2026 Corporate Catalyst Bullish Impact 75
Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate
Vertex Pharmaceuticals' Q2 earnings report shows a mixed but generally positive picture. While adjusted EPS met expectations, the significant beat in sales by 3.15% and a 12.45% ye…
Jul 21, 2026 Corporate Catalyst Bearish Impact 75
Vertex shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight rating and lowered its price target from $19 to $15.
This headline represents a significant corporate catalyst for Vertex Pharmaceuticals. Analyst downgrades from major investment banks like Morgan Stanley often trigger immediate neg…
Jul 13, 2026 Corporate Catalyst Bullish Impact 60
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585
UBS analyst Michael Yee maintained a 'Buy' rating on Vertex Pharmaceuticals and raised the price target from $545 to $585. This action signals continued confidence in the company's…
Jul 13, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560
Truist Securities analyst Danielle Brill maintained a 'Buy' rating on Vertex Pharmaceuticals (VRTX) and raised the price target from $542 to $560. This action signals an analyst's …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.